 | This article or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days , please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{ in use }} during the active editing session. Click on the link for template parameters to use. This article was last edited by Edwardx (talk | contribs) 4 seconds ago. (Update timer) |
Michelle Xia | |
|---|---|
| Born | Xia Yu 1966or1967(age 58) [1] |
| Nationality | Chinese |
| Known for | Founder, CEO, chairwoman and president of Akeso Biopharma |
Michelle Xia (born 1966 or 1967) is a Chinese billionaire businesswoman, and the founder, CEO, chairwoman and president of the pharmaceutical startup Akeso Biopharma.
Xia was raised in Gansu province, the daughter of two university-educated engineers. [1]
She earned a degree in biochemistry from Sun Yat-sen University in Guangzhou in 1988, and a doctorate in molecular biology and microbiology from Newcastle University in the UK. [1]
Under Xia, Akeso have developed Ivonescimab, which appears to outperform Pembrolizumab (marketed as Keytruda), produced by Merck in the US. [2]
In March 2025, she was included in the Time100 Health 2025. [3]
As of July 2025, Forbes estimates her net worth at US$1.2 billion. [1]